Triomics, an oncology AI company helping cancer centers operationalize complex clinical information, announced it has raised $22 million in Series B financing led by Battery Ventures, with participation from existing investors Nexus Venture Partners, Lightspeed, and Y Combinator, alongside strategic backers Oncology Ventures and Precision Health Informatics, a wholly owned subsidiary of Texas Oncology. The round brings the company’s total funding raised to more than $36 million.
The company said the new capital will be used to accelerate adoption across health systems, oncology networks, and life sciences organizations, while also expanding Triomics’ AI, engineering, and forward deployed teams. The funding will additionally support the advancement of the company’s AI agents for clinical care and research workflows.
Founded in 2021 by Sarim Khan and Hrituraj Singh, Triomics is building an AI platform designed to process longitudinal cancer patient records and convert unstructured clinical information into structured and explainable outputs integrated directly into healthcare workflows. The company’s platform supports proactive clinical trial matching, pre visit chart review and preparation, and oncology data abstraction for registry, quality improvement, and operational use cases.
Triomics is already working with leading cancer centers including Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Yale Cancer Center and its partner Smilow Cancer Hospital, as well as Mount Sinai Tisch Cancer Center and major community oncology practices including Texas Oncology.
According to the company, cancer centers use Triomics to reduce manual chart review burdens, improve visit preparation, expand clinical trial access, and generate higher quality structured oncology data for research and operational purposes. Published results cited by the company show users increased trial matches by 40% and trial enrollments by more than 30%, while reducing chart review times by 67%. The platform has also received peer reviewed validation in Nature Digital Medicine and has been presented at American Society of Clinical Oncology events.
Battery Ventures principal Brandon Gleklen is joining Triomics’ board of directors as part of the investment.
KEY QUOTES:
“Oncology faces an information burden at a scale legacy systems were never designed to handle, and that burden can stand in the way of better outcomes. Clinicians, research coordinators and medical assistants are working against records that have become too large and too dynamic to process manually. We built Triomics to turn that complexity into usable intelligence inside the workflow, purpose-built for oncology. This financing allows us to bring that infrastructure to many more cancer centers and improve care for cancer patients.
Oncology is the hardest place to build AI, yet the most important. Getting a model to reason reliably across thousands of pages of notes, pathology, imaging and evolving trial criteria, and show its work, is what separates a demo from software that clinicians actually use. We’ve spent four years building that foundation and this round lets us push even further.”
Sarim Khan, Co-Founder And CEO, Triomics
“We are excited to partner with Triomics, our selected solution for oncology clinical trial matching, to extend our collaboration to an AI-enabled method for cancer registry abstraction and reporting. This activity is labor intensive, subjective and challenging to complete in a timely manner. Our goal is to produce autonomous chart abstraction of clinical registry quality that can be rapidly reviewed and finalized for reporting by human registrars to comply with mandatory state, federal and professional society reporting obligations.”
Lee Schwamm, MD, Chief Digital Health Officer, Yale New Haven Health System, And Associate Dean, Digital Strategy & Transformation, Yale School Of Medicine
“Triomics built what oncology has always needed: AI infrastructure that actually works on the full patient record. We are live at some of the top cancer centers and demonstrating measurable outcomes—faster enrollment, less manual chart review—and the same underlying AI infrastructure already powers multiple distinct workflows with no redundant integrations. That kind of platform leverage, inside a customer base this strong, is rare at this stage.”
Brandon Gleklen, Principal, Battery Ventures
